Cresset Asset Management LLC Has $3.36 Million Position in ARK Genomic Revolution ETF $ARKG

Cresset Asset Management LLC grew its stake in shares of ARK Genomic Revolution ETF (BATS:ARKG) by 55.9% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 121,062 shares of the company’s stock after buying an additional 43,403 shares during the quarter. Cresset Asset Management LLC owned approximately 0.27% of ARK Genomic Revolution ETF worth $3,362,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Atlantic Union Bankshares Corp acquired a new stake in shares of ARK Genomic Revolution ETF during the 2nd quarter valued at $34,000. Strategic Wealth Investment Group LLC acquired a new position in ARK Genomic Revolution ETF in the 2nd quarter worth about $38,000. FWL Investment Management LLC increased its holdings in ARK Genomic Revolution ETF by 750.8% in the 2nd quarter. FWL Investment Management LLC now owns 2,765 shares of the company’s stock worth $67,000 after purchasing an additional 2,440 shares in the last quarter. Total Investment Management Inc. bought a new position in ARK Genomic Revolution ETF in the second quarter valued at about $70,000. Finally, NewEdge Advisors LLC raised its position in ARK Genomic Revolution ETF by 49.4% in the first quarter. NewEdge Advisors LLC now owns 5,384 shares of the company’s stock valued at $112,000 after purchasing an additional 1,780 shares during the last quarter.

ARK Genomic Revolution ETF Price Performance

Shares of ARKG stock opened at $28.12 on Friday. The business’s 50-day moving average price is $30.20 and its 200-day moving average price is $29.19. ARK Genomic Revolution ETF has a 12 month low of $17.50 and a 12 month high of $34.39.

ARK Genomic Revolution ETF Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.